

Idhifa[®] (enasidenib) Prior Authorization Form**Member Name:** _____ **Date of Birth:** _____ **Member ID#:** _____**Drug Information****Pharmacy Billing (NDC:** _____ **) Start Date (or date of next dose):** _____**Dose:** _____ **Regimen:** _____**Pharmacy Information****Pharmacy NPI:** _____ **Pharmacy Name:** _____**Pharmacy Phone:** _____ **Pharmacy Fax:** _____**Prescriber Information****Prescriber NPI:** _____ **Prescriber Name:** _____**Prescriber Phone:** _____ **Prescriber Fax:** _____ **Specialty:** _____**Criteria****For Initial Authorization:**

- Will enasidenib be used as a single agent? Yes No
- Has an isocitrate dehydrogenase-2 (IDH2) mutation been detected? Yes No
- Please indicate the diagnosis and information:
 Acute Myeloid Leukemia (AML)
 - Is AML newly-diagnosed? Yes No
 - Is member unable to tolerate intensive induction chemotherapy? Yes No
 - Is AML relapsed or refractory? Yes No
- Other:** _____

Additional Information: _____
_____**For Continued Authorization:**

- Date of last dose: _____
 - Does member have any evidence of progressive disease while on enasidenib? Yes No
 - Has the member experienced adverse drug reactions related to enasidenib therapy? Yes No
- If yes, please specify adverse reactions:*
- _____
-
- _____

Prescriber Signature: _____ **Date:** _____***I certify that the indicated treatment is medically necessary and all information is true and correct to the best of my knowledge.****Please do not send in chart notes. Specific information will be requested if necessary. Failure to complete this form in full will result in processing delays.*

Fax completed prior authorization request form to 888-601-8461 or submit Electronic Prior Authorization through CoverMyMeds[®] or SureScripts. All requested data must be provided. Incomplete forms or forms without the chart notes will be returned. Pharmacy Coverage Guidelines are available at AetnaBetterHealth.com/Oklahoma.

CONFIDENTIALITY NOTICE

This document, including any attachments, contains information which is confidential or privileged. If you are not the intended recipient, be aware that any disclosure, copying, distribution, or use of the contents of this information is prohibited. If you have received this document in error, please notify the sender immediately by telephone to arrange for the return of the transmitted documents or to verify their destruction.